New Drug Application for naloxegol accepted by United States Food and Drug Administration
19 November 2013 | By AstraZeneca
The NDA filing was based on comprehensive data from the core Phase III KODIAC programme...
List view / Grid view
News
Sanofi discontinues clinical development of investigational JAK2 agent Fedratinib (SAR302503)
18 November 2013 | By Sanofi
Sanofi announced the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor...
AbbVie releases first of six phase III results from investigational all-oral, interferon-free, 12-week regimen, showing 96% SVR12 in Genotype 1 hepatitis C patients new to therapy
18 November 2013 | By AbbVie
AbbVie's multinational HCV program is the largest all-oral, interferon-free clinical program in GT1 patients being conducted to date...
BMG LABTECH and InvivoSciences collaborate to accelerate drug discovery in engineered 3D tissues
BMG LABTECH, Inc. - the Microplate Reader Company - and InvivoSciences, Inc. - a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery - announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies.…
Merck’s new drug application for an investigational intravenous (IV) formulation of NOXAFIL® (posaconazole) receives FDA priority review
18 November 2013 | By Merck
Marketing authorization application also filed with the European Medicines Agency...
RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD
18 November 2013 | By GlaxoSmithKline
RELVAR® ELLIPTA® is now licensed across 31 European countries...
3D cell-based models for regenerative medicine and drug discovery
18 November 2013 | By AMSBIO
Presented by Dr Elad Katz, a senior scientist at AMSBIO, a new on-demand webinar explores the potential of 3D cell-based models for regenerative medicine and drug discovery.
Abbott named Top Dealmaker for sixth consecutive year by The Deal
18 November 2013 | By Abbott
Abbott was recognized by The Deal as the best all-around dealmaker in healthcare...
NovoEight® passed the review by the Committee on Drugs of Pharmaceutical Affairs in Japan
18 November 2013 | By Novo Nordisk
NovoEight® has passed the review by the Committee on Drugs of Japan's Pharmaceutical Affairs and Sanitation Council...
Additional interim data for Merck’s investigational anti-PD-1 immunotherapy, MK-3475, shows estimated overall survival rate of 81% at one year in patients with advanced melanoma
18 November 2013 | By Merck
“I am excited by the results seen for MK-3475 to date as a single agent..."
Amgen presents interim overall survival data from Phase 3 study of Talimogene Laherparepvec in patients with metastatic melanoma
18 November 2013 | By Amgen
Differences in survival rates were pronounced in the subset of patients with stage IIIB, IIIC or IV M1a disease...
Boehringer Ingelheim goes “Blue” in supporting World Diabetes Day activities
15 November 2013 | By Boehringer Ingelheim
"Run for Diabetes" raises €15,000 towards supporting "Life for a Child Programme..."
Novartis announces positive clinical trial results for novel H7N9 vaccine
14 November 2013 | By Novartis
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59® adjuvant...
Bristol-Myers Squibb Foundation marks World Diabetes Day with four grants addressing link between diabetes, depression and distress
14 November 2013 | By Bristol-Myers Squibb
“There is a need for the development of short- and long-term diabetes care models and self-management programs..."
Amgen to highlight new Evolocumab (AMG 145) data at upcoming American Heart Association Scientific Sessions 2013
14 November 2013 | By Amgen
First long-term data of a PCSK9 Inhibitor to be featured in clinical science: special reports session...
